secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010313
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics reports FY2022 revenue $6.7M, net loss $14.9M; cash $32M
----------------------------------------------------------------------

- Q4 2022 revenue $1.3M from licensed molecule sale to Wugen; full year $6.7M (nil in prior year).
- R&D expenses $9.3M for FY2022 (vs $8.2M), G&A $8.3M (vs $5.2M); net loss $14.9M (vs $12.9M).
- Cash, cash equivalents & short-term investments total $32.0M as of Dec 31, 2022; funding sufficient through next 12 months.
- Phase 1/1b trials for HCW9218 in solid tumors and advanced pancreatic cancer ongoing; Phase 1 completion targeted in 2023.
- CRADA with NCI for Phase 1b/2 pancreatic study; scientific paper on HCW9302 published in Frontiers in Immunology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/0000950170-23-010313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/hcwb-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer